分子靶向药物治疗子宫内膜癌的研究进展

Advances in molecular-targeted drugs for endometrial carcinoma

子宫内膜癌是我国女性生殖系统第二大恶性肿瘤,在发达国家位居第一位。子宫内膜癌的治疗早期以手术切除为主,辅以放化疗结合其他药物治疗。耐药性大大降低了化疗的成功率,从而增加了疾病复发的可能性。早期和低危疾病患者预后良好,而晚期、复发或转移性子宫内膜癌患者预后极差。目前,现有药物治疗晚期、复发或转移性子宫内膜癌的临床疗效不佳。因此,迫切需要寻找潜在的新靶点和新的治疗方法来提高疗效和改善预后。子宫内膜癌的分子分型有助于识别潜在的药物靶点,为患者的治疗和预后提供更好的临床指导。本文根据子宫内膜癌的分子分型,对子宫内膜癌具有潜在治疗作用的药物靶点和分子靶向药物的研究进展作一综述。

Endometrial cancer is the second most common malignancy of the female reproductive system in China and ranks first in developed countries. The main treatment for early-stage endometrial cancer is surgical resection,followed by radiotherapy, chemotherapy and other drugs. Drug resistance greatly reduces the efficacy of chemotherapy, thus increasing the possibility of recurrence. Patients with early-stage and low-risk disease have a good prognosis, whereas those with advanced stage, recurrent or metastatic endometrial cancer have a poor prognosis. Currently available drugs have poor clinical outcomes for patients with advanced, recurrent, or metastatic endometrial cancer. Therefore, it is urgent to find potential new targets and therapeutic approaches to enhance the efficacy and improve the prognosis. The molecular classification of endometrial cancer can help identify potential drug targets and provide better clinical guidance for patient treatment and prognosis. This article reviews the research progress of potential therapeutic drug targets and molecular-targeted drugs for endometrial cancer based on the molecular classification of endometrial cancer.